Alkermes Reports Positive Phase 1b ADHD Data for ALKS 7290
DUBLIN — September 21, 2026 Alkermes announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290,...
OX2R Agonist
Advertisement
Nxera Pharma to Receive $8.6M Milestone Payment from Centessa for OX2R Development
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
Takeda Wins Japan Approval for ORZEYFUL in Narcolepsy
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
Alkermes Highlights Strong Phase 2 Data for Alixorexton at SLEEP 2026
DUBLIN, June 17, 2026 Alkermes plc announced detailed positive results from the Phase 2 Vibrance-2 clinical trial evaluating alixorexton,...
Advertisement
